Project Grant R41DC017108

This federal Project Grant award from the National Institute on Deafness and Other Communication Disorders (NIDCD), under the Research Related to Deafness and Communication Disorders program (CFDA 93.173), provides $275,737 to Rewire Neuroscience LLC to develop and validate a machine learning platform for predicting the ototoxic potential of pharmaceutical compounds. The key objectives are to: 1) optimize and apply an innovative machine learning model that can categorize drugs as ototoxic or...

The National Institute on Deafness and Other Communication Disorders (NIDCD) awarded Jacaranda Biosciences, Inc. a $304,762 SBIR Phase 1 Project Grant under the Research Related to Deafness and Communication Disorders program (CFDA 93.173). The funding will support the development of novel JBI compounds that function through the unfolded protein response (UPR) to prevent the ototoxicity and hearing loss caused by cisplatin chemotherapy treatment. The key objectives are to optimize the efficacy...

This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) federal grant program, provides $306,872 to Bioprinting Laboratories Inc. to establish a platform for high-throughput developmental neurotoxicity (DNT) testing using engineered brain organoids. The key products and services to be delivered include: Developing genetically engineered, induced pluripotent stem cells with a promoter-reporter assay system to...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...

The National Institute of Environmental Health Sciences (NIEHS) awarded Nexilico, Inc. a $275,765 Project Grant (CFDA 93.113 - Environmental Health) to develop a predictive computational-experimental platform to characterize microbial biotransformation of xenobiotic compounds and identify naturally occurring gut microbial strains that can mitigate xenobiotic toxicity as novel probiotics. The project aims to provide cost-effective yet accurate predictions to identify microbial species capable...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $358,245 Project Grant to the Massachusetts Eye And Ear Infirmary on May 15, 2024 for the project "IN SILICO SCREEN AND IN VIVO EVALUATION OF FDA-APPROVED DRUGS TO TREAT NOISE-INDUCED HEARING LOSS". The grant supports a two-year effort to screen FDA-approved drugs and evaluate the most promising compounds for their ability to protect against noise-induced hearing loss in cell...

The National Institute on Aging (NIA) awarded a $949,062 Project Grant (CFDA 93.866) to Somatoceutics LLC to develop a non-toxic, peptide-based nanomaterial (SMC-101 nanotubes) for delivering drugs across the blood-brain barrier to treat Alzheimer's disease and other dementias. The objectives are to optimize the nanotubes for drug-loading and transcytosis across a blood-brain barrier model in vitro, and then evaluate their toxicity and ability to deliver the drug galantamine to the central...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

The U.S. Department of Defense awarded a $350,848 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of Michigan to fund a 2-year research project titled "A Novel Strategy to Prevent Central Auditory Disorders After Blast Exposure." The project aims to develop a nanoparticle-based delivery system to administer therapeutics that can prevent hearing loss and other auditory impairments resulting from blast exposures...

This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $222,750 to the University of Alabama at Birmingham (UAB) to define the molecular target of arsine gas-induced acute kidney injury and associated morbidity. The key objectives of this 2-year award are to: 1) characterize a mouse model of arsine toxicity, including dose- and time-dependent responses, biomarkers of acute kidney injury, and evaluation of multi-organ...